Skip to main content
. 2014 Dec 21;16(5):267–276. doi: 10.1007/s10269-014-2391-1

Table 2.

Distribution of best response obtained during bevacizumab FOLFIRI and of secondary chirurgical resections depending on age and in intention to treat.

Response Global population Patients < 70 Patients > 70
n = 91 n = 20
Complete response 3 (3%) 3 (3%)
Partial response 48 (43%) 39 (43%) 9 (45%)
Stable disease 29 (26%) 25 (27%) 4 (20%)
Progression 21 (20%) 17 (19%) 4 (20%)
Toxicity 10 (8%) 7 (7%) 3 (15%)
Resection 30 27 3
Liver resection 24 21 3